Trial results for a Phase 2 study (NCT03697564) investigating the combination of nivolumab, cabiralizumab, and gemcitabine in patients with Stage IV pancreatic cancer were posted on ClinicalTrials.gov on 2025-08-06. The study, which enrolled 2 participants, reported 1 participant with progression-free survival (PFS) and 1 participant with overall survival (OS) in the combination arm.
Background
The study investigated the combination of nivolumab, cabiralizumab, and gemcitabine for the treatment of Stage IV pancreatic cancer. The trial aimed to assess if this combination could provide prolonged disease control in patients with advanced pancreatic cancer.
Trial design
The study (NCT03697564) was a Phase 2 trial that enrolled 2 participants with Stage IV pancreatic cancer. Interventions included gemcitabine, nivolumab 10 mg/ml intravenous solution [opdivo], and cabiralizumab. The purpose of the study was to evaluate if this combination could provide prolonged disease control in patients with advanced pancreatic cancer.
Key results
The trial reported results for the combination arm of Gemcitabine + Nivolumab + Cabiralizumab. For the outcome of "Number of Participants With Progression Free Survival (PFS)", 1 participant was reported. For the outcome of "Number of Participants With Overall Survival (OS)", 1 participant was reported.
What this means
Given the very limited enrollment of 2 participants in this Phase 2 study, the reported outcomes of 1 participant with progression-free survival and 1 participant with overall survival provide only preliminary insights. These results are insufficient to draw definitive conclusions regarding the efficacy or safety profile of the nivolumab, cabiralizumab, and gemcitabine combination for Stage IV pancreatic cancer. Further research with larger patient cohorts would be necessary to assess the potential of this therapeutic approach.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03697564, titled "Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer," were posted on 2025-08-06 on clinicaltrials.gov.